Sanofi India Limited has announced its Q4 financial results, reporting a 33.7% YoY decline in net profit to ₹91.3 crore, compared to ₹137.7 crore in the same period last year. Meanwhile, revenue increased by 9.7% to ₹514.9 crore from ₹469.2 crore YoY.
Key Financial Highlights:
- Net Profit: ₹91.3 crore, down 33.7% YoY
- Revenue: ₹514.9 crore, up 9.7% YoY
- EBITDA: ₹118.3 crore, up 18.8% YoY
- EBITDA Margin: 23% vs 21.2% YoY
- Final Dividend: ₹117 per share
The company attributed its revenue growth to double-digit expansion in its diabetes portfolio, particularly with Toujeo® and Soliqua®, reinforcing confidence in its product offerings. It also emphasized new partnerships in the Cardiovascular (CV) and Central Nervous System (CNS) categories, which are expected to drive further growth.
Rodolfo Hrosz Managing Director, Sanofi India:
“In a year of significant transformation for the company, we have successfully brought to market Soliqua® – our best-in-class diabetes drug for the premix segment, which has received encouraging acceptance. Our efforts of reaching more HCPs through partnerships for the Cardiovascular and CNS (Central Nervous System) categories have advanced as planned, with initial promising results. We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of established and innovative products in India.”
Sanofi India has continued its ‘India for India’ strategy, focusing on go-to-market initiatives, operational efficiency, and innovation. Managing Director Rodolfo Hrosz highlighted that Soliqua® has seen strong acceptance, and the company remains committed to improving efficiency while expanding its product availability in India.
